Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

emavusertib (CA-4948)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Curis, Dr. Reddy’s

Drug class:

FLT3 inhibitor, IRAK-4 inhibitor

Related drugs:

‹

›

FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	CA-4948 Sensitive: C2 – Inclusion Criteria CA-4948 Sensitive : C2	CA-4948 Sensitive: C2 – Inclusion Criteria CA-4948 Sensitive : C2
U2AF1 mutation	Acute Myelogenous Leukemia	U2AF1 mutation	Acute Myelogenous Leukemia	CA-4948 Sensitive: C2 – Inclusion Criteria CA-4948 Sensitive : C2	CA-4948 Sensitive: C2 – Inclusion Criteria CA-4948 Sensitive : C2
SF3B1 mutation	Acute Myelogenous Leukemia	SF3B1 mutation	Acute Myelogenous Leukemia	CA-4948 Sensitive: C2 – Inclusion Criteria CA-4948 Sensitive : C2	CA-4948 Sensitive: C2 – Inclusion Criteria CA-4948 Sensitive : C2
SF3B1 mutation	Myelodysplastic Syndrome	SF3B1 mutation	Myelodysplastic Syndrome	CA-4948 Sensitive: C2 – Inclusion Criteria CA-4948 Sensitive : C2	CA-4948 Sensitive: C2 – Inclusion Criteria CA-4948 Sensitive : C2
U2AF1 mutation	Myelodysplastic Syndrome	U2AF1 mutation	Myelodysplastic Syndrome	CA-4948 Sensitive: C2 – Inclusion Criteria CA-4948 Sensitive : C2	CA-4948 Sensitive: C2 – Inclusion Criteria CA-4948 Sensitive : C2
FLT3 mutation	Myelodysplastic Syndrome	FLT3 mutation	Myelodysplastic Syndrome	CA-4948 Sensitive: C2 – Inclusion Criteria CA-4948 Sensitive : C2	CA-4948 Sensitive: C2 – Inclusion Criteria CA-4948 Sensitive : C2